Janux Therapeutics, Inc.
JANX
$24.28
$1.014.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.28% | 27.95% | -370.87% | 59.63% | -25.53% |
| Total Depreciation and Amortization | 1.37% | 0.39% | 0.79% | -4.89% | 0.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.98% | -73.38% | 348.60% | -27.46% | 58.46% |
| Change in Net Operating Assets | -49.57% | -102.69% | 274.50% | -65.32% | -305.75% |
| Cash from Operations | -1.79% | -649.66% | 77.74% | 32.46% | -49.85% |
| Capital Expenditure | -783.33% | -68.00% | 73.68% | 51.78% | 61.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,101.00% | 167.49% | 106.66% | -68.04% | -1,075.59% |
| Cash from Investing | -1,103.34% | 167.68% | 106.64% | -67.83% | -1,122.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.77% | 23,347.54% | -40.36% | -99.14% | 38,669.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.86% | 23,347.54% | -40.36% | -99.14% | 38,669.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.36% | 3,239.82% | 106.10% | -202.35% | 9,330.00% |